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Summary KL-6, one of the MUC1 antigens, is a mucin-like high-molecular-weight
glycoprotein, which is strongly expressed on type II pneumocytes. Serum levels of KL-
6 have been shown to correlate with activity of interstitial pneumonia (IP). During
embryonic development, MUC1 expression coincides with the onset of epithelial sheet
and glandular formation. To investigate the potential role of KL-6 in lung
morphogenesis, we examined KL-6 expression by immunohistochemistry on autopsied
lung tissue specimens of 35 neonates and infants with gestational age from 23 to 40
weeks. Hyaline membranes (HMs) were detected in 13 of 35 cases. Simultaneously,
antibody against surfactant protein A (SP-A) was employed in the study which is a
distinct marker for type II pneumocytes. In all cases studied with gestational age
above 23 weeks, staining for KL-6 was strongly positive in alveolar epithelial cells and
in HMs found in 13 cases, whereas immunoreaction for PE10 varied depending on
gestational age and duration of postnatal survival. Our findings suggest that KL-6 is
expressed earlier in premature lung and may act as an important factor contributing
to morphogenesis and function of developing lung in early gestation.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
KL-6 is a mucin-like high-molecular-weight glyco-
protein and is classified as a human MUC1 mucin.1,2
MUC1 is one of the mucins, which is densely
expressed on the cell surface of most cancers of
epithelial origin and also expressed at the secretory
border of normal respiratory, gastrointestinal and
genitorurinary epithelial tissues. Transfection stu-
dies have revealed that MUC1 participates in many
biological functions, including anti-adhesion activ-
ity,3–5 immunosuppressive activity,6 and as a ligand
for selectins.7 During human and mouse embryonic
developments, MUC1/Muc1 expression was found
to coincide with epithelial sheet and glandular
formation.8–10 In all cases, during development in
the mammary and salivary glands and in the lungs,
pancreas, stomach and kidney, the induction of
Muc-1 gene transcription preceded the functional
activity of these organs.8,11
KL-6 was originally discovered as a circulating
pulmonary adenocarcinoma-associated antigen. Of
note, however, was the finding of an abnormally
increased level of KL-6 in sera of patients with
interstitial pneumonia (IP), especially IP in active
condition.12 Moreover, the clinical usefulness of KL-
6 as a marker of disease activity of IP has been
shown to be superior to that of other serum
markers such as lactate dehydrogenase (LDH),
type-III procollagen N-terminal peptide and C-
reactive protein.12,13 KL-6 is thus a useful marker
of disease activity for IP and a serum diagnostic
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marker for IP. However, expression of KL-6 during
embryonic development has not yet been docu-
mented.
Our previous study demonstrated that in various
kinds of IP, intense staining for KL-6 and surfactant
protein A (SP-A) was detected in the proliferating
type II pneumocytes as well as in hyaline membrane
(HM), a frequent phenomenon in the acute stage of
IP. SP-A is the major protein component of
pulmonary surfactant synthesized and secreted by
type II pneumocytes. The appearance of SP-A
reflects the functional ability of alveolar cells. To
investigate the potential role of KL-6 in lung
morphogenesis and whether it appears prior to
the functional activity of SP-A secretion, we
examined KL-6 and SP-A expression by immunohis-
tochemical staining of postmortem lung specimens
from neonates and infants of 23–40 weeks’ gesta-
tional age.
Materials and methods
Lung tissue specimens of 35 neonates and infants
were obtained from autopsy at the Department of
Pathology of Kochi Medical School, Kochi, Japan.
The gestational age of the 35 cases ranged from 23
to 40 weeks, and details of postnatal survival are
shown in Table 1. Most of the cases died of
cerebroventricular abnormalities and/or pulmon-
ary immaturity within 1 day after birth. These
immaturities were proportional to gestational ages,
but not hypoplasia. In the cases with 23–27 weeks’
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Table 1 Characteristics of 35 neonates and infants and expressions of KL-6 and SP-A in these cases.
No. Gestational
age (weeks)
Sex Postnatal survival
(days/years)
Hyaline
membrane
KL-6 SP-A
1 23 M o1 day Present + 
2 23 M o1 day Present + 
3 23 F o1 day Present + 
4 24 M 4 day + 
5 24 M 226 day Present + +
6 25 M o1 day Present + 
7 26 M o1 day + 
8 26 M o1 day + 
9 26 F 6 day + +
10 27 F o1 day + 
11 27 M 12 day + +
12 27 M 180 day Present + +
13 28 M 2 day Present + 
14 28 F o1 day + +B
15 28 M o1 day Present + 
16 28 M o1 day + 
17 29 F o1 day Present + 
18 29 M o1 day Present + +
19 29 F 1 day + 
20 31 M o1 day + 
21 31 M o1 day Present + 
22 32 F o1 day + +B
23 33 M o1 day Present + +B
24 34 F 3 day + +
25 34 M 33 day + +B
26 35 F 2 day + +
27 35 M 60 day + +
28 37 M 3 day + +
29 38 M o1 day + +
30 38 F o1 day Present + +
31 38 M o1 day + +
32 39 F 5 day + +
33 40 F o1 day + +B
34 40 F 165 day + +
35 40 F 1 year + +
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gestation, very preterm infants had body weights of
0.3–0.9 kg. Chromosomal anomalies were demon-
strated in five cases. Based on the presence of HM
on histopathological examination, HM disease was
diagnosed in 13 cases (Table 1). The ethics
committee of Kochi Medical School, Kochi, Japan
approved this study, the relatives of all patients
having provided written, informed consent before
enrolment.
Tissue slices were fixed in 20% phosphate-
buffered formalin and embedded in paraffin and
sectioned at 3 mm for histological and immunohis-
tochemical evaluation. Immunohistochemical
stains were performed using the avidin-biotin
peroxidase complex (ABC) method (LSAB kit, Dako,
Carpinteria, CA, USA) with antibodies against KL-6
(10 ng/ml, from Dr. N. Kohno), surfactant protein A
(PE10; Dako; dilution, 1:100), epithelial membrane
antigen (EMA; Dako; dilution, 1:50), factor VIII-
related antigen (Factor VIII; Dako; dilution, 1:400),
human urinary protein-1 (Hup-1; Dako; dilution,
1:100), pancytokeratin (AE1/AE3; Boehringer-Man-
nheim, Indianapolis, IN, USA; dilution, 1:400), and
cytokeratin 19 (ScyTek Laboratories, Logan, Utah,
USA; dilution, 1:30). Antigen retrievals using 0.1%
pronase digestion or microwave pretreatment were
performed for antibodies to factor VIII, AE1/AE3
and CK19. Appropriate positive and negative con-
trols were stained in parallel. Staining procedures
were performed according to the manufacturers’
instructions.
Results
The major results of immunohistochemical studies
of KL-6 and SP-A are shown in Table 1. KL-6
expression was conspicuous in the alveolar and
bronchiolar epithelial cells in all the cases studied
with gestational age from 23 to 40 weeks (Figs. 1B,
2A, 3A), and was also discernible in HMs found in 13
cases. However, PE10, a distinct marker for type II
pneumocytes, exhibited quite diverse immunoreac-
tivity depending on gestational age and duration of
postnatal survival. In cases with less than 28 weeks’
gestational age, no staining for PE10 was detected
in the alveolar epithelial cells (Fig. 1C) or in HMs
except in four with prolonged postnatal survival
(case nos. 5, 9, 11, and 12) (Fig. 2B). Case no. 5
with 24 weeks’ gestational age and 226 days
postnatal survival expressed PE10 in both alveolar
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Figure 1 Premature lung from a neonatal case with gestational age of 23 weeks (case no. 3). (A) KL-6-positive alveolar
cells and immunoreactive vascular endothelium (arrows) are conspicuous (B), but no PE10-positive reaction is observed
(C). H&E, ABC stain,  330.
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cells and HMs. Notably, reactivity for PE10 was
initially demonstrated as granular material in the
alveolar spaces of the lower respiratory tract (Fig.
2B). From 28 weeks’ to 31 weeks’ gestational age,
cases exhibited transitional immunostaining for
PE10 between negativity and positivity. After that,
in the cases with >31 weeks’ gestational age, PE10
labeling was predominant in the alveolar epithelial
cells (Fig. 3B), and was also present in HMs. In cases
positive for both KL-6 and PE10, the intensity of
PE10 staining was stronger than that for KL-6. KL-6-
positive reaction was observed in vascular endothe-
lium (Fig. 1B, arrows, 2B, arrows). In addition, in all
cases tested, stainings for epithelial markers such
as EMA, AE1/AE3 and CK19 were present in the
alveolar and bronchiolar epithelial cells, and Factor
VIII was detected in endothelial cells. However,
their immunoreactivities in HMs varied in different
regions of the same case, similar to adult IP.
Likewise, Hup-1, a specific marker for Clara cell
protein, was indefinitely expressed on HMs,
although Clara cells were widely positive.
Discussion
In this study, we found KL-6 expression by im-
munohistochemical staining in lung tissues from
neonates and infants with gestational ages of 23 to
40 weeks. The immunoreactivities observed de-
monstrate that expression of KL-6 appears early in
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Figure 2 Coexpression of KL-6 (A) and PE10 (B) in a 27-
week-gestational-age case with 180-day postnatal life
(case no. 12). Labeling for PE10 is present as granular
material in the alveolar spaces. Note the positivity of
vascular endothelium for KL-6 (arrows). ABC stain,
 200.
Figure 3 Immunostaining of KL-6 and PE10 in a case with
>31 weeks’ gestational age (case no. 35). Both KL-6 (A)
and PE10 (B) are strongly expressed in the alveolar
epithelial cells. ABC stain,  200.
KL-6 expression in premature lung 967
premature lung, which precedes its functional
activity of SP-A secretion, strongly suggesting that
KL-6 plays an important role in lung morphogenesis
in early gestation.
KL-6 was first described by Kohno and cow-
orkers.1 Because it bears a sialylated carbohydrate,
KL-6 was later termed MUC1.2 KL-6 expression is
dramatically increased in atypical and/or regener-
ating type II pneumocytes in tissues from patients
with IP.12 Clinical studies have shown that serum
level of KL-6 is elevated in more than 70% of
patients with IP, such as idiopathic pulmonary
fibrosis, hypersensitivity pneumonitis, radiation
pneumonitis, pulmonary sarcoidosis and collagen
vascular disease-associated interstitial pneumoni-
tis.12,13–15 Moreover, levels of KL-6 are significantly
higher in patients with active disease than in those
with inactive disease.12–15 KL-6 has thus been
identified as a serum diagnostic marker for IP. Here
we demonstrate strong immunostaining for KL-6 in
the alveolar and bronchiolar epithelial cells in
cases with gestational age above 23 weeks. The
results of the present study expand previous
observations on KL-6 and provide the first evidence
of KL-6 expression in premature lung. Significantly,
expression of KL-6 in alveolar cells was in this study
much earlier than that of SP-A, which is synthesized
and secreted by type II pneumocytes, suggesting
that KL-6 expression in the alveolar cells is prior to
their functional activity. KL-6 now termed MUC1,
has been reported to play a role in morphogen-
esis.8,11,16 In the developing mouse embryo, Muc1
protein and mRNA appearance was found to be
coincident with epithelial sheets and glandular
formation.8 Moreover, the induction of Muc-1 gene
transcription preceded the functional activity of
the organs known to express it.8,11 It has been
shown that MUC1 mucin is a potent glandular
morphogen.16 However, Muc-1 null mice developed
normally and remained healthy and fertile.17 Muc-1
deficient mice exhibited no differences in survival
rate and appeared phenotypically normal in all
respects. The authors hypothesized that other
mucins and mucin-like genes might compensate
for Muc-1 deficiency.17 In the yeast Saccharomyces
cerevisiae, deletion of MUC1 abolished pseudohy-
phal differentiation and invasive growth.18,19
Furthermore, MUC1 is overexpressed in carcinomas
and has been implicatied in tumor progression and
metastasis, resulting in a less differentiated phe-
notype and a poor prognosis.20–22 This could be
attributed to anti-adhesion properties of MUC1,
including inhibiting cell–cell and cell–extracellular
matrix (ECM) interactions, decreasing cell aggrega-
tion, and repressing E-cadherin-mediated cell–cell
adhesion and intergrin-mediated cell–ECM adhe-
sion.3–5 Of note, KL-6 was found to be chemotactic
for human fibroblasts.23 Fibroblasts contribute to
the synthesis of the insulin-like growth factors
(IGFs), which are implicated in regulation of
embryonic and fetal growth and development.24–26
Expression of KL-6 in early gestation (from at least
23 weeks’ gestation) may therefore support the
hypothesis of its essential roles in morphogenesis
and lung development.
It is important to note that immunostaining for
KL-6 and SP-A was dissociated in this study,
although both could be detected in type II
pneumocytes. We have shown that SP-A production
depends on gestational age and longevity of
postnatal life. Except in cases with long postnatal
life, before 28 weeks’ gestation SP-A cannot be
expressed in alveolar cells although KL-6 can. SP-A
expression was first discernible in week 28 of
gestation and was detectable from 32 weeks’
gestation. Our finding of the appearance of SP-A
by 28 weeks’ gestation accords with that of
initiation of transcription of the SP-A gene in fetal
lung after approx. 70% of gestation is completed,27
and further clarifies the time of SP-A expression in
fetal lung. Interestingly, four specific cases (o28
week gestational age) with prolonged postnatal
survival in our study exhibited SP-A expression in
the alveolar cells as well as in HMs. Since atmo-
spheric oxygen stimulates SP-A gene expression and
morphologic development,28 we reasoned that
postnatal life contributes to the synthesis of SP-A
in prematurely born infants.
We found as well that in cases with lack of SP-A
expression in alveolar cells, SP-A was also not
detected in HMs. After SP-A expression was
initiated in the alveolar cells, reaction for SP-A
was noted in HMs. This finding suggests that SP-A is
not an essential component of HM and that its
involvement in HM formation should be related to
the responsiveness of lung resulting from its
maintaining low alveolar surface tension. In con-
trast, KL-6 expression was demonstrated in HMs
found in 13 cases, indicating that KL-6 is the
primary component of HM.
One intriguing, and potentially useful, finding of
the present study is that vascular endothelium
exhibits KL-6 expression in some areas. In most
patients with IP, significantly increased levels of KL-
6 have been detected in sera,12–15 as in bronch-
oalveolar lavage fluid (BALF) and epithelial lining
fluid (ELF).9,16
In conclusion, this study provides a novel insight
into understanding KL-6, showing that it is ex-
pressed early even in very premature lung at above
23 weeks’ gestation. In particular, we have demon-
strated that SP-A is not an essential component of
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HM but that KL-6 is. Our findings suggest that KL-6
may play constructive roles in morphogenesis and
the function of developing lung in early gestation.
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